Epigenetic mechanisms of tumorigenesis

Hormone and Metabolic Research

Volumn 37, Issue 6, 2005, Pages 361-368

  Farrell, W E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Epigenetics; Familial; Pituitary tumors; TSG (Tumor suppressor gene)

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; HISTONE; PROTEIN P16;

ALLELE; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL DIVISION; CHROMATIN; CPG ISLAND; EPIGENETICS; FAMILIAL CANCER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENOME IMPRINTING; GROWTH REGULATION; HUMAN; HYPOPHYSIS TUMOR; METHYLATION; ONCOGENE; PRIORITY JOURNAL; PTAG GENE; REVIEW; SOMATIC CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM PROTEINS; PITUITARY NEOPLASMS;

EID: 22444439588     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-870153     Document Type: Review

References (54)

1. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis. Trends in Genet 2000; 16: 168-173
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genetics 1999; 21: 163-167
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa J-P. Alterations in DNA methylation: a fundamental aspect of neoplasia. In: Vande Woude GF, Kleine G (eds). Advances in Cancer Research. San Diego, CA: Academic Press, 1998: 141-196
4. Zingg J-M, Jones P. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinog 1997; 21: 461-467
5. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends in Genetics 1997; 12: 444-449
6. Jones PL, Veenstra GJC, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics 1999; 19: 87-191
7. Momparler RL Cancer epigenetics. Oncogene 2003; 22: 6479-6483
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 2002; 3: 415-428
9. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662-673
10. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993; 3: 226-231
11. Sherr C. Cancer cell cycles. Science 1996; 274: 1672-1677
12. Esteller M, Fraga MF, Guo MZ, Garcia-Foncillas J, Hedenfalk I, Godwin AK, Trojan J, Vaurs-Barriere C, Bignon YJ, Ramus S, Benitez J, Caldes T, Akiyama Y, Yuasa Y, Launonen V, Canal MJ, Rodriguez R, Capella G, Peinado MA, Borg A, Aaltonen LA, Ponder BA, Baylin SB, Herman JG. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10: 3001-3007
13. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 1989; 83: 155-158
14. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991; 48: 880-888
15. Woloschak M, Yu A, Post KD. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Molec Carcinogen 1997; 19: 221-224
16. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrel WE. Hypermethylation of the p16/CDKN2A/MTS1 gene and loss of protein expression is associated with non-functional pituitary adenomas but not somatotrophinomas Genes. Chromosomes and Cancer 1999; 24: 328-336
17. Yoshimoto K, Tanaka C, Yamada S, Kimura T, Iwahana H, Sano T, Itakura M. Infrequent mutation of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol 1997; 136: 74-80
18. a, MTS-1) gene polymorphism and methylation status in human pituitary tumors. Clinical Endocrinology 1999; 51: 317-325
19. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R, Paulus W. CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol 2001; 193: 491-497
20. Ruebel KH, Jin L, Zhang S, Scheithauer BW, Lloyd RV. Inactivation of p16 gene in human pituitary non-functioning tumors by hypermethylation is more common in null cell adenomas. Endocrine Pathol 2001; 12: 281-289
21. Burke CW, Adams CB, Esiri MM, Morris C, Bevan JS. Transsphenoidal surgery for Cushing's disease: does what is removed determine the endocrine outcome? Clin Endocrinol (Oxf) 1990; 33: 525-537
22. Kruse A, Klinken L, Holck S, Lindholm J. Pituitary histology in Cushing's disease. Clin Endocrinol 1992; 37: 254-259
23. Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 2002; 56: 25-28
24. Bloodworth JMB Jr. Assessment of the pituitary hyperplasia/neoplasia interface. Path Res Pract 1988; 183: 626-630
25. Horvath E, Kovacs K, Scheithauer BW. Pituitary hyperplasia. Pituitary 1999; 1: 69-179
26. Simpson DJ, McNicol AM, Murray DC, Bahar A, Turner HE, Wass JAH, Esiri MM, Clayton RN, Farrell WE. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin Can Res 2004; 10: 1780-1788
27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826
28. Farrell WE, Clayton RN. Molecular pathogenesis of pituitary tumors. Frontiers in Neuroendocrinology 2000; 21: 174-198
29. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN, Farrell WE. Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas. Cancer Res 1999; 59: 1562-1566
30. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000; 60: 1211-1216
31. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, de Campos JM, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL, Rey JA. CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin Can Res 2003; 9: 5601-5606
32. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Can 2003; 106: 334-341
33. Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, de Campos JM, Isla A, Rey JA. CpG island methylation status and mutation analysis of the RBI gene essential promoter region and protein-binding pocket domain in nervous system tumours. British J Cancer 2003; 88: 109-114
34. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimichi A. DAP kinase activates a p19(ARF)/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001; 3: 1-7
35. Simpson DJ, Clayton RN, Farrell WE. Methylation and loss of Death Associated Protein Kinase gene in sporadic pituitary tumors. Oncogene 2002; 21: 1217-1224
36. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B, Klibanski A. Loss off expression of GADD45γ a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J Clin Endocrinol Metab 2002; 87: 1262-1267
37. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE. Loss of expression of the growth inhibitory gene GADD45 gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 2004; 23: 936-944
38. Surani MAH, Barton SC, Norris ML. Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature 1984; 308: 548-550
39. McGrath J, Solter D. Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 1984; 37: 79-183
40. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 1993; 362: 747-749
41. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE. Relaxation of insulin-like growth factor-ii gene imprinting implicated in wilms-tumor. Nature 1993; 362: 749-751
42. Melmed S. Mechanisms for pituitary Tumorigenesis: the plastic pituitary. J Clin Invest 2003; 112: 1603-1618
43. Weinstein LS, Chen M, Liu J. Gs(alpha) mutations and imprinting defects in human disease. Ann NY Acad Sci 2002; 968: 173-197
44. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, Bonthron DT. Imprinting of the G(s) alpha gene GNAS in the pathogenesis of acromegaly. J Clin Invest 2001; 107: R31-R36
45. Gonzalgo ML, Liang G, Spruck CH, Zingg JM, Rideout WH, Jones PA. Identification and characterisation of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Can Res 1997; 57: 594-599
46. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN, Farrell WE. Isolation and Characterization of a Novel Pituitary Tumor Apoptosis Gene (PTAG). Mol Endo 2004; 18: 1827-1839
47. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Molec Biol 1987; 196: 261-282
48. Yin D, Tamaki N, Kokunai T, Yasuo K, Yonezawa K. Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. Journal Clin Neurosci 1999; 6: 326-331
49. Yin D, Kondo S, Takeuchi J, Morimura T, Vaux DL. Bcl-2 gene prevents apoptosis in murine ACTH-secreting adenoma cells induced by bromocriptine. International J Oncol 1994; 4: 187-191
50. Wheeler JMD, Loukola A, Aaltonen LA, Mortensen NJM, Bodmer WF. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI plus sporadic colorectal cancers. J Med Genet 2000; 37: 588-592
51. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000; 156: 1773-1779
52. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26: 16-17
53. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. AmJ Hum Genet 1997; 60: 765-771
54. Yuen ST, Chan TL, Ho JWC, Chan ASY, Chung LP, Lam PWY, Tse CW, Wyllie AH, Leung SY. Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers. Oncogene 2002; 21: 7585-7592